Navigation Links
WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai

SHANGHAI, China, Feb. 10 /PRNewswire-Asia/ -- WuXi AppTec (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the U.S., announced it had recently held a successful 2009 supplier conference in Shanghai.

(Logo: )

The half-day event, with a theme of "Stick together to create a brilliant 2009," assembled 110 representatives of suppliers who provide the company with top-quality instruments and other equipment, raw materials, reagents, consumables, and related products and services. The conference provided a venue to exchange new ideas and strategies to improve the efficiency of the supply chain and to positively impact future financial and operational performance.

WuXi AppTec also took the occasion to provide special recognition to suppliers who helped the company achieve greater efficiency and cost savings. WuXi evaluates its suppliers on the basis of quality of management, quality of products, on-time delivery, customer service, and cost. To acknowledge their highly proactive and responsive service, the company presented the Preferred Supplier Award to Agilent Technologies Inc. and Service Awards to Fulltime Holdings Ltd. and Sigma-Aldrich (Shanghai) Trading Co., Ltd. Dr. Richard M. Soll, Vice President of Medicinal Chemistry, commented, "Outsourcing is now widely recognized as a highly effective and cost-efficient approach to pharmaceutical R&D. WuXi's mission is to improve the success of research and shorten the time of development of the world's leading biopharmaceutical and medical device companies. We are succeeding by offering a broad range of capabilities: an international leadership team with extensive experience in the industries we serve; a large staff of highly educated and trained scientists; broad technical expertise; world-class facilities in both China and the U.S.; and an intense focus on meeting the needs of a diversified customer base."

"2008 was a year of significant achievement for WuXi AppTec,'' said Mr. Xiaozhong Liu, Executive Vice President. ''Our governing principle is to develop new capabilities and add new capacity to provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. In that regard, we completed the acquisition of AppTec Laboratory Services, Inc., which gave our company new testing capabilities to serve biotech and medical device customers. We have now completed the integration of AppTec and look forward to building on its solid base of business.

''We also made substantial progress in 2008 in constructing two new facilities-the GLP Drug Evaluation Center in Suzhou, one of the largest in Asia, and an expansion of the manufacturing facility in the Jinshan area of Shanghai. Both facilities are now fully constructed and undergoing validation. Both provide opportunities for significant revenue growth in 2010 and beyond.

''For these initiatives and our ongoing business to be successful, we need continued support from a dedicated group of high-quality suppliers," Mr. Liu concluded. ''WuXi has been fortunate to continue to experience rapid growth in our global business despite global financial crisis. This conference is an expression of the continued commitment of WuXi and its suppliers to establish a perfect cost-efficient partnership to serve healthcare manufacturers better."

About WuXi AppTec

WuXi AppTec is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi AppTec provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi AppTec's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi AppTec is an operating subsidiary of WuXi PharmaTech traded under NYSE symbol WX, formally WuXi PharmaTech (Cayman) Inc. For more information, please visit: .

    For more information, please contact:

     Sherry Shao
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4002

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Successfully Defends Multi-Million Dollar Arbitration Filed by CRG and CRGP; Related Parties Withdraw Remaining Demands for Arbitration Against Genesis
2. Pearly Penile Papule Patients Can Successfully Be Treated with Targeted CO2 Technology at La Jolla Cosmetic Surgery Centre
3. Genesis Pharmaceuticals Successfully Defends Itself in a Multi-Million Dollar Arbitration, Two Other Arbitration Proceedings Against Genesis are Withdrawn
4. Chemical come-on successfully lures lovesick lampreys to traps
5. University of Ottawa Heart Institute Scientists Successfully Develop Novel Biomaterial to Help Grow New Blood Vessels
6. MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA
7. The Ensign Group Successfully Graduates Second Nursing Home From CMS Special Focus Program
8. Pilot Program Successfully Addresses Mental Health Issues in Pennsylvanias Children
9. Perot Systems Successfully Implements Hospital Information System in Abu Dhabi
10. Stereotaxis Magnetic Navigation System Used to Successfully Treat an Inoperable Congenital Heart Defect in a 10-Year Old Patient
11. PreMD Successfully Completes Project for Health & Beauty Company
Post Your Comments:
(Date:6/26/2016)... ... 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop ... The fitness app plans to fix the two major problems leading the fitness industry today:, ... all type program , They don’t eliminate all the reasons people quit their ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: